Nisa Investment Advisors LLC Has $50,000 Position in Haemonetics Corporation (NYSE:HAE)

Nisa Investment Advisors LLC lessened its holdings in Haemonetics Corporation (NYSE:HAE) by 33.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 793 shares of the medical instruments supplier’s stock after selling 402 shares during the period. Nisa Investment Advisors LLC’s holdings in Haemonetics were worth $50,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of HAE. TD Waterhouse Canada Inc. purchased a new stake in Haemonetics in the 4th quarter worth about $25,000. Covestor Ltd lifted its position in shares of Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. purchased a new stake in shares of Haemonetics in the fourth quarter worth approximately $62,000. KBC Group NV boosted its holdings in shares of Haemonetics by 19.9% during the first quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock worth $154,000 after purchasing an additional 401 shares during the period. Finally, Vise Technologies Inc. grew its position in Haemonetics by 8.7% during the fourth quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock valued at $221,000 after purchasing an additional 225 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

HAE has been the topic of a number of research reports. Wall Street Zen downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Citigroup raised Haemonetics from a “neutral” rating to a “buy” rating and set a $90.00 price target for the company in a research note on Wednesday, July 9th. Barrington Research reiterated an “outperform” rating and set a $95.00 price target on shares of Haemonetics in a report on Friday, July 11th. Raymond James Financial restated a “strong-buy” rating and issued a $105.00 price objective (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $97.30.

Haemonetics Stock Performance

NYSE:HAE opened at $72.55 on Friday. The firm has a market capitalization of $3.49 billion, a PE ratio of 21.92, a PEG ratio of 1.19 and a beta of 0.39. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Haemonetics Corporation has a 1 year low of $55.30 and a 1 year high of $94.99. The firm’s fifty day simple moving average is $71.63 and its 200 day simple moving average is $67.93.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The business had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. During the same period in the previous year, the company posted $0.90 earnings per share. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. On average, sell-side analysts anticipate that Haemonetics Corporation will post 4.55 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.